RU2012109383A - Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело - Google Patents
Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело Download PDFInfo
- Publication number
- RU2012109383A RU2012109383A RU2012109383/10A RU2012109383A RU2012109383A RU 2012109383 A RU2012109383 A RU 2012109383A RU 2012109383/10 A RU2012109383/10 A RU 2012109383/10A RU 2012109383 A RU2012109383 A RU 2012109383A RU 2012109383 A RU2012109383 A RU 2012109383A
- Authority
- RU
- Russia
- Prior art keywords
- crystal
- crystal according
- nrp2
- diffracts
- fab fragment
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title claims abstract 23
- 239000012634 fragment Substances 0.000 title claims abstract 5
- 102000002111 Neuropilin Human genes 0.000 title 1
- 108050009450 Neuropilin Proteins 0.000 title 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims abstract 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims abstract 8
- 101150106321 Nrp2 gene Proteins 0.000 claims abstract 8
- 230000005855 radiation Effects 0.000 claims abstract 7
- 102000014105 Semaphorin Human genes 0.000 claims abstract 4
- 108050003978 Semaphorin Proteins 0.000 claims abstract 4
- 229940119473 Semaphorin antagonist Drugs 0.000 claims abstract 2
- 238000007423 screening assay Methods 0.000 claims abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
Abstract
1. Кристалл комплекса, образованного фрагментом Nrp2и Fab-фрагментом антитела против panNrp, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=148 Å, b=106 Å, c=92,4 Å и пространственную группу C2.2. Кристалл по п.1, который дифрагирует рентгеновское излучение до разрешения 2,75Å.3. Кристалл по п.1, где указанный Fab-фрагмент содержится в SEQIDNO: 10.4. Композиция, содержащая кристалл по п.1.5. Кристалл комплекса, образованного фрагментом Nrp2и Fab-фрагментом антитела против panNrp, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=121 Å, b=121 Å, c=203 Å и пространственную группу P321.6. Кристалл по п.5, который дифрагирует рентгеновское излучение до разрешения 3,1Å.7. Кристалл по п.5, где указанный Fab-фрагмент содержится в SEQIDNO: 10.8. Композиция, содержащая кристалл по п.5.9. Кристалл по п.1 или 5 для применения в скринирующем анализе для идентификации антагониста семафорина.
Claims (9)
1. Кристалл комплекса, образованного фрагментом Nrp2a1a2b1b2 и Fab-фрагментом антитела против panNrpA, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=148 Å, b=106 Å, c=92,4 Å и пространственную группу C2.
2. Кристалл по п.1, который дифрагирует рентгеновское излучение до разрешения 2,75Å.
3. Кристалл по п.1, где указанный Fab-фрагмент содержится в SEQIDNO: 10.
4. Композиция, содержащая кристалл по п.1.
5. Кристалл комплекса, образованного фрагментом Nrp2a1a2b1b2 и Fab-фрагментом антитела против panNrpA, который подавляет связывание семафорина с Nrp2, где указанный кристалл дифрагирует рентгеновское излучение, производя картину дифракции, отображающую трехмерную структуру указанного комплекса, имеющего приблизительно следующие параметры элементарной ячейки: a=121 Å, b=121 Å, c=203 Å и пространственную группу P3221.
6. Кристалл по п.5, который дифрагирует рентгеновское излучение до разрешения 3,1Å.
7. Кристалл по п.5, где указанный Fab-фрагмент содержится в SEQIDNO: 10.
8. Композиция, содержащая кристалл по п.5.
9. Кристалл по п.1 или 5 для применения в скринирующем анализе для идентификации антагониста семафорина.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2007/069185 | 2007-05-12 | ||
| PCT/US2007/069185 WO2008143666A2 (en) | 2007-05-17 | 2007-05-17 | Crystal structures of neuropilin fragments and neuropilin-antibody complexes |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009146823/10A Division RU2454427C2 (ru) | 2007-05-17 | 2007-05-17 | АНТИТЕЛО ПРОТИВ panNrpA (ВАРИАНТЫ) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012109383A true RU2012109383A (ru) | 2013-09-20 |
Family
ID=38963109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012109383/10A RU2012109383A (ru) | 2007-05-12 | 2012-03-12 | Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8318163B2 (ru) |
| EP (1) | EP2158215B1 (ru) |
| JP (1) | JP2010530359A (ru) |
| KR (1) | KR101523788B1 (ru) |
| CN (1) | CN101743253B (ru) |
| AU (1) | AU2007353779B2 (ru) |
| BR (1) | BRPI0721707A2 (ru) |
| CA (1) | CA2687556A1 (ru) |
| ES (1) | ES2541051T3 (ru) |
| IL (1) | IL201983A (ru) |
| MX (1) | MX2009012282A (ru) |
| RU (1) | RU2012109383A (ru) |
| WO (1) | WO2008143666A2 (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| JP5940061B2 (ja) | 2010-06-18 | 2016-06-29 | ジェネンテック， インコーポレイテッド | 抗ａｘｌ抗体及び使用方法 |
| EP2686020B1 (en) | 2011-03-17 | 2017-02-22 | The University of Birmingham | Re-directed immunotherapy |
| CN104662044B (zh) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
| CN103992376B (zh) * | 2013-02-18 | 2017-05-17 | 上海市第一人民医院 | 一种抑制新生血管的小肽及其应用 |
| CN103992377B (zh) * | 2013-02-18 | 2017-05-17 | 上海市第一人民医院 | 一种抑制新生血管的小肽及其应用 |
| ES2847383T3 (es) | 2013-03-15 | 2021-08-03 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| JP2017518307A (ja) | 2014-06-02 | 2017-07-06 | チルドレンズ メディカル センター コーポレーション | 免疫調節のための方法および組成物 |
| CN113980116A (zh) * | 2014-09-05 | 2022-01-28 | Rsem有限合伙公司 | 用于治疗和预防炎症的组合物和方法 |
| KR102293755B1 (ko) | 2016-01-06 | 2021-08-24 | 오더-메이드 메디컬 리서치 인코포레이티드 | 고친화성 항vegf 항체 |
| CN108779172B (zh) | 2016-01-06 | 2022-02-08 | 定制药品研究株式会社 | 抑制vegf与nrp1结合的抗体 |
| KR20240113990A (ko) | 2016-06-27 | 2024-07-23 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암 치료 조합 |
| JOP20190134A1 (ar) * | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
| EP3612215B1 (en) | 2017-04-20 | 2024-08-28 | aTyr Pharma, Inc. | Compositions for treating lung inflammation |
| CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| US11542331B2 (en) | 2017-06-06 | 2023-01-03 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands |
| EP3773718A4 (en) | 2018-04-06 | 2022-01-19 | aTyr Pharma, Inc. | COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES |
| US11702482B2 (en) | 2018-12-17 | 2023-07-18 | Revitope Limited | Twin immune cell engager |
| TWI859339B (zh) | 2019-09-24 | 2024-10-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
| EP4037711A4 (en) | 2019-10-03 | 2024-02-14 | Atyr Pharma, Inc. | COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES |
| GB202207116D0 (en) * | 2022-05-16 | 2022-06-29 | Quadram Inst Bioscience | Method and Compositions for Tumorigenesis Inhibition |
| CN114949224B (zh) * | 2022-06-06 | 2023-03-14 | 山东大学第二医院 | Nrp2激动剂在制备复发性流产治疗药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE68929151T2 (de) | 1988-10-28 | 2000-07-20 | Genentech, Inc. | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
-
2007
- 2007-05-17 CN CN2007800537931A patent/CN101743253B/zh not_active Expired - Fee Related
- 2007-05-17 US US12/598,625 patent/US8318163B2/en not_active Expired - Fee Related
- 2007-05-17 BR BRPI0721707-2A patent/BRPI0721707A2/pt not_active IP Right Cessation
- 2007-05-17 JP JP2010508353A patent/JP2010530359A/ja not_active Withdrawn
- 2007-05-17 CA CA002687556A patent/CA2687556A1/en not_active Abandoned
- 2007-05-17 KR KR1020097026233A patent/KR101523788B1/ko not_active Expired - Fee Related
- 2007-05-17 ES ES07762242.1T patent/ES2541051T3/es active Active
- 2007-05-17 EP EP20070762242 patent/EP2158215B1/en active Active
- 2007-05-17 WO PCT/US2007/069185 patent/WO2008143666A2/en not_active Ceased
- 2007-05-17 MX MX2009012282A patent/MX2009012282A/es active IP Right Grant
- 2007-05-17 AU AU2007353779A patent/AU2007353779B2/en not_active Ceased
-
2009
- 2009-11-08 IL IL201983A patent/IL201983A/en not_active IP Right Cessation
-
2012
- 2012-03-12 RU RU2012109383/10A patent/RU2012109383A/ru not_active Application Discontinuation
- 2012-07-03 US US13/541,411 patent/US8466264B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2158215A2 (en) | 2010-03-03 |
| US20100150919A1 (en) | 2010-06-17 |
| JP2010530359A (ja) | 2010-09-09 |
| CN101743253A (zh) | 2010-06-16 |
| CN101743253B (zh) | 2013-05-08 |
| US8318163B2 (en) | 2012-11-27 |
| CA2687556A1 (en) | 2008-11-27 |
| EP2158215B1 (en) | 2015-04-22 |
| WO2008143666A2 (en) | 2008-11-27 |
| KR101523788B1 (ko) | 2015-06-26 |
| HK1144580A1 (en) | 2011-02-25 |
| IL201983A0 (en) | 2010-06-16 |
| BRPI0721707A2 (pt) | 2013-01-15 |
| WO2008143666A3 (en) | 2009-02-05 |
| AU2007353779A1 (en) | 2008-11-27 |
| IL201983A (en) | 2015-03-31 |
| KR20100020967A (ko) | 2010-02-23 |
| US8466264B2 (en) | 2013-06-18 |
| ES2541051T3 (es) | 2015-07-15 |
| MX2009012282A (es) | 2009-11-25 |
| US20120322989A1 (en) | 2012-12-20 |
| AU2007353779B2 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012109383A (ru) | Кристаллические структуры фрагментов нейропилина и комплексов нейропилин-антитело | |
| Meneghini et al. | Nature of “disorder” in the ordered double perovskite Sr 2 FeMoO 6 | |
| Moon et al. | High pressure study of low compressibility tetracalcium aluminum carbonate hydrates 3CaO· Al2O3· CaCO3· 11H2O | |
| Pekov et al. | The sulfite anion in ettringite-group minerals: a new mineral species hielscherite, Ca3Si (OH) 6 (SO4)(SO3)· 11H2O, and the thaumasite–hielscherite solid-solution series | |
| Santacruz et al. | Structure of stratlingite and effect of hydration methodology on microstructure | |
| Medarde et al. | 1D to 2D Na+ ion diffusion inherently linked to structural transitions in Na 0.7 CoO 2 | |
| Guidobaldi et al. | Multi-scale analysis of the mechanical improvement induced by lime addition on a pyroclastic soil | |
| JP2010530359A5 (ru) | ||
| Zahid et al. | Investigating the effects of solarcure curing method on the compressive strength, microstructure and polymeric reaction of fly ash based geopolymer | |
| EA200701292A1 (ru) | Композиции, содержащие антитела против рецептора igf-1, и способы получения антител | |
| Gatta et al. | Minerals in cement chemistry: A single-crystal neutron diffraction and Raman spectroscopic study of thaumasite, Ca3Si (OH) 6 (CO3)(SO4)· 12H2O | |
| Aziz et al. | Microstructure and porosity evolution of alkali activated slag at various heating temperatures | |
| Renaudin et al. | Crystal chemistry of iron containing cementitious AFm layered hydrates | |
| More et al. | Cation distribution in nanocrystalline Al3+ and Cr3+ co-substituted CoFe2O4 | |
| Merz et al. | Electronic structure of single-crystalline Sr (Fe 1− x Co x) 2 As 2 probed by x-ray absorption spectroscopy: Evidence for effectively isovalent substitution of Fe 2+ by Co 2+ | |
| Shaikhutdinov et al. | Ultra-thin silicate films on metals | |
| Machida et al. | Long-period stacking structures in yttrium trihydride at high pressure | |
| RU2013144545A (ru) | Композиции алюмосиликатных цеолитов типа х с низким содержанием цеолита типа lta | |
| Gili et al. | Synthesis and characterization of mordenite-type zeolites with varying Si/Al ratio | |
| Piro et al. | Crystal and molecular structure and spectroscopic behavior of isotypic synthetic analogs of the oxalate minerals stepanovite and zhemchuzhnikovite | |
| Miyajima et al. | Niigataite, CaSrAl3 (Si2O7)(SiO4) O (OH): Sr-analogue of clinozoisite, a new member of the epidote group from the Itoigawa-Ohmi district, Niigata Prefecture, central Japan | |
| Lemma et al. | Natural pozzolan with different volcanic glass and zeolite content: Effect on the performance of blended cement | |
| Sugimoto et al. | Chlorartinite, a volcanic exhalation product also found in industrial magnesia screed | |
| DE502004010328D1 (de) | Hydrogelhaltiges kompositmaterial, hergestellt durch elektrisch-ausgelöste präzipitation einer festphase | |
| Zubkova et al. | Crystal structure of natrite, γ-Na2CO3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150513 |